THE TARGET CONCENTRATION APPROACH TO CLINICAL DRUG DEVELOPMENT

被引：56

作者：

HOLFORD, NHG

机构：

[1] Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland

来源：

CLINICAL PHARMACOKINETICS | 1995年 / 29卷 / 05期

关键词：

D O I：

10.2165/00003088-199529050-00001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：287 / 291

页数：5

共 17 条

[1]

BREIMER DD, 1994, 2ND INT S MEAS KIN I

[2] PHARMACOLOGICALLY GUIDED PHASE-I CLINICAL-TRIALS BASED UPON PRECLINICAL DRUG DEVELOPMENT [J].

COLLINS, JM ;

GRIESHABER, CK ;

CHABNER, BA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (16) :1321-1326

[3] COMPARATIVE EFFICIENCIES OF RANDOMIZED CONCENTRATION-CONTROLLED AND DOSE-CONTROLLED CLINICAL-TRIALS [J].

ENDRENYI, L ;

ZHA, JH .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) :331-338

[4] THEOPHYLLINE TARGET CONCENTRATION IN SEVERE AIRWAYS OBSTRUCTION - 10 OR 20 MG/L - A RANDOMIZED CONCENTRATION-CONTROLLED TRIAL [J].

HOLFORD, N ;

BLACK, P ;

COUCH, R ;

KENNEDY, J ;

BRIANT, R .

CLINICAL PHARMACOKINETICS, 1993, 25 (06) :495-505

[5] TIME AND THEOPHYLLINE CONCENTRATION HELP EXPLAIN THE RECOVERY OF PEAK FLOW FOLLOWING ACUTE AIRWAYS OBSTRUCTION - POPULATION ANALYSIS OF A RANDOMIZED CONCENTRATION CONTROLLED TRIAL [J].

HOLFORD, N ;

HASHIMOTO, Y ;

SHEINER, LB .

CLINICAL PHARMACOKINETICS, 1993, 25 (06) :506-515

[6] POPULATION PHARMACODYNAMICS OF ROMAZARIT [J].

HOLFORD, NHG ;

WILLIAMS, PEO ;

MUIRHEAD, GJ ;

MITCHELL, A ;

YORK, A .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (03) :313-320

[7]

Holford NHG, 1992, IN VIVO STUDY DRUG A, P401

[8]

LEVY G, 1993, CLIN PHARMACOL THER, V53, P387, DOI 10.1038/clpt.1993.39

[9]

LEVY G, 1993, CLIN PHARMACOL THER, V53, P385, DOI 10.1038/clpt.1993.37

[10] CONCENTRATION-CONTROLLED OR EFFECT-CONTROLLED CLINICAL-TRIALS WITH SPARSE DATA [J].

LEVY, G ;

EBLING, WF ;

FORREST, A .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (01) :1-8

← 1 2 →